title: Variation of chromogranin A serum levels after radical retropubic prostatectomy for prostate adenocarcinoma.
abstract: This study evaluated perioperative and postoperative variations in serum CgA levels induced by radical retropubic prostatectomy (RRP) and their relationship with serum PSA levels in prostate cancer patients. Thirty consecutive patients with clinically localized adenocarcinoma of the prostate undergoing RRP were prospectively analyzed. Serum levels of CgA and total PSA were analyzed in each case preoperatively (time 0), at removal of the prostate (time 1), 1 h after the end of RRP (time 2) and then at regular postoperative intervals till 12 weeks (time 14). During the postoperative period no adjuvant therapies were performed and none of the 30 cases showed biochemical (PSA > 0.2 ng/mL) and/or clinical progression. Mean preoperative serum levels of CgA were 57 +/- 14 ng/mL. Immediately after the surgical removal of the prostate gland (time 1), in all 30 cases there was a significant (time 0-time 1: p = .001) increase in serum PSA, but a nonsignificant modification in serum CgA levels (60 +/- 15 ng/mL). After time 1, serum PSA levels progressively decreased to below the detection limit of 0.2 ng/mL. On the contrary, at time 2, serum CgA levels were postoperatively increased (time 2 = 145 +/- 47) and they remained significantly higher than preoperative values (time 0) till the 21-day postoperative interval (time 11). Moreover, at the last control (time 14) mean and median CgA levels were very similar to those shown preoperatively (time 14: 58 +/- 18 ng/mL). In patients with untreated clinically localized adenocarcinoma of the prostate submitted to RRP, surgical and postoperative stress, more than surgical manipulation of the prostate gland, could produce a significant increase in serum CgA levels maintained for a longer period when compared to the increase in serum PSA levels.
authors.affiliation: Department of Urology, U. Bracci, University La Sapienza, Rome, Italy. sciarrajr@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: Sciarra
authors.forename: V
authors.initials: V
authors.lastname: Gentile
authors.forename: S
authors.initials: S
authors.lastname: Monti
authors.forename: G
authors.initials: G
authors.lastname: Mariotti
authors.forename: A
authors.initials: A
authors.lastname: Pastore
authors.forename: F
authors.initials: F
authors.lastname: Di Silverio
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000601:surgery*; D000368:Aged; D053379:Chromogranin A; D002864:Chromogranins / Q000097:blood*; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000601:surgery*
chemical_list: C506150:CHGA protein, human; D053379:Chromogranin A; D002864:Chromogranins; D017430:Prostate-Specific Antigen